Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Price Negotiation -- Waiting for the Other Shoe to Drop

This article was originally published in RPM Report

Executive Summary

At present, the federal government is prohibited from negotiating outpatient prescription drug prices with pharmaceutical companies on behalf of Medicare Part D. But, Senator Barack Obama (and perhaps John McCain, whose stance on this policy is unclear) favors a health system in which the government can bring its bargaining power to the table. What happens when the other shoe drops?

You may also be interested in...

Medicare Rebates: Bigger is Better, But is Big Government Best?

An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.

Health Care Reform and the Changing Dynamics Between Payers and Drug Makers

Why drug makers should pay close attention to the pressures bearing down on payers.

Individualized Health Plans - The Bite of Demand-Side Discipline

Since the end of World War II, the employer-based health plan has been part of the social compact for many Americans. While Senator Barack Obama’s proposal for expanded coverage is greeted enthusiastically by those who favor change, Senator John McCain’s proposal offers the boldest departure from business as usual.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts